Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at ...

Retrieved on: 2024-12-09 21:49:25

Tags for this article:

Click the tags to see associated articles and topics

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at .... View article details on hiswai:

Summary

The article discusses Rigel Pharmaceuticals' study on R289 for lower-risk myelodysplastic syndrome (LR-MDS), linking epidemiology to treatments involving orphan drugs, blood transfusion management, and luspatercept, emphasizing clinical outcomes and patient response rates.

Article found on: www.biospace.com

View Original Article